Autoimmune versus oligodendrogliopathy: The pathogenesis of multiple sclerosis

Archivum Immunologiae et Therapiae Experimentalis

Volumn 58, Issue 5, 2010, Pages 325-333

  Nakahara, Jin ^a   Aiso, Sadakazu ^a   Suzuki, Norihiro ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Autoimmune; Multiple sclerosis; Oligodendrogliopathy; Pathogenesis

Indexed keywords

ALEMTUZUMAB; AUTOANTIBODY; AUTOANTIGEN; BETA1A INTERFERON; CD4 ANTIBODY; CD4 ANTIGEN; GLATIRAMER; IMMUNOSUPPRESSIVE AGENT; MITOXANTRONE; MYELIN; NATALIZUMAB; PLACEBO; TUMOR NECROSIS FACTOR ANTIBODY;

ALLERGIC ENCEPHALOMYELITIS; ANTIGEN ANTIBODY REACTION; AUTOIMMUNE DISEASE; AUTOIMMUNITY; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; DEMYELINATION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; DRUG PENETRATION; HUMAN; HUMORAL IMMUNITY; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NONHUMAN; OLIGODENDROGLIA; OLIGODENDROGLIOPATHY; PATHOPHYSIOLOGY; RELAPSE; REMYELINIZATION; REVIEW;

ANIMALS; AUTOIMMUNITY; CLINICAL TRIALS AS TOPIC; DEMYELINATING DISEASES; GUILLAIN-BARRE SYNDROME; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MODELS, IMMUNOLOGICAL; MULTIPLE SCLEROSIS; NEUROGLIA; OLIGODENDROGLIA; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 77956188760     PISSN: 0004069X     EISSN: 16614917     Source Type: Journal    
DOI: 10.1007/s00005-010-0094-x     Document Type: Review

References (49)

1. MH Barnett JW Prineas 2004 Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion Ann Neurol 55 458 468 10.1002/ana.20016 15048884
2. I Bartholomäus N Kawakami F Odoardi, et al. 2009 Effector T cell interactions with meningeal vascular structures in nascent autoimmune CNS lesions Nature 462 94 98 10.1038/nature08478 19829296
3. M Bradl H Lassmann 2010 Oligodendrocytes: biology and pathology Acta Neuropathol 119 37 53 10.1007/s00401-009-0601-5 19847447
4. EC Breij BP Brink R Veerhuis, et al. 2008 Homogeneity of active demyelinating lesions in established multiple sclerosis Ann Neurol 63 16 25 10.1002/ana.21311 18232012
5. DA Brown PE Sawchenko 2007 Time course and distribution of inflammatory and neurodegenerative events suggest structural bases for the pathogenesis of experimental autoimmune encephalomyelitis J Comp Neurol 502 236 260 10.1002/cne.21307 17348011
6. RK Burt Y Loh B Cohen, et al. 2009 Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study Lancet Neurol 8 244 253 10.1016/S1474-4422(09) 70017-1 19186105
7. A Chang A Nishiyama J Peterson, et al. 2000 NG2-positive oligodendrocyte progenitor cells in adult human brain and multiple sclerosis lesions J Neurosci 20 6404 6412 10964946
8. J Charcot 1868 Histologie de la sclérose en plaque Gazette des Hôpitaux 41 554 566
9. AJ Coles DA Compston KW Selmaj, et al. 2008 Alemtuzumab vs. interferon beta-1a in early multiple sclerosis N Engl J Med 359 1786 1801 10.1056/NEJMoa0802670 18946064
10. DJ Cua J Sherlock Y Chen, et al. 2003 Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain Nature 421 744 748 10.1038/nature01355 12610626
11. HP Eugster K Frei R Bachmann, et al. 1999 Severity of symptoms and demyelination in MOG-induced EAE depends on TNFR1 Eur J Immunol 29 626 632 10.1002/(SICI)1521-4141(199902)29:02<626::AID-IMMU626>3.0.CO;2-A 10064079
12. K Frei C Siepl P Groscurth, et al. 1987 Antigen presentation and tumor cytotoxicity by interferon-gamma-treated microglial cells Eur J Immunol 17 1271 1278 10.1002/eji.1830170909 3115791
13. GC Furtado MC Marcondes JA Latkowski, et al. 2008 Swift entry of myelin-specific T lymphocytes into the central nervous system in spontaneous autoimmune encephalomyelitis J Immunol 181 4648 4655 18802067
14. HP Hartung R Gonsette N König, et al. 2002 Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial Lancet 360 2018 2025 10.1016/S0140-6736(02)12023-X 12504397
15. AP Henderson MH Barnett JD Parratt, et al. 2009 Multiple sclerosis: distribution of inflammatory cells in newly forming lesions Ann Neurol 66 739 753 10.1002/ana.21800 20035511
16. KP Johnson BR Brooks JA Cohen, et al. 1995 Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial Neurology 45 1268 1276 7617181
17. MR Kotter WW Li C Zhao, et al. 2006 Myelin impairs CNS remyelination by inhibiting oligodendrocyte precursor cell differentiation J Neurosci 26 328 332 10.1523/JNEUROSCI.2615-05.2006 16399703
18. T Kuhlmann V Miron Q Cui, et al. 2008 Differentiation block of oligodendroglial progenitor cells as a cause for remyelination failure in chronic multiple sclerosis Brain 131 1749 1758 10.1093/brain/awn096 18515322
19. AP Lieberman PM Pitha HS Shin, et al. 1989 Production of tumor necrosis factor and other cytokines by astrocytes stimulated with lipopolysaccharide or a neurotropic virus Proc Natl Acad Sci USA 86 6348 6352 10.1073/pnas.86.16.6348 2474832
20. CF Lucchinett W Bruck H Lassmann 2004 Evidence for pathogenic heterogeneity in multiple sclerosis Ann Neurol 56 308 10.1002/ana.20182
21. C Lucchinetti W Brück J Parisi, et al. 2000 Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination Ann Neurol 47 707 717 10.1002/1531-8249(200006)47:6<707::AID-ANA3>3.0. CO;2-Q 10852536
22. E Millefiorini C Gasperini C Pozzilli, et al. 1997 Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome J Neurol 244 153 159 10.1007/s004150050066 9050955
23. J Nakahara S Aiso 2006 Fc receptor-positive cells in remyelinating multiple sclerosis lesions J Neuropathol Exp Neurol 65 582 591 10.1097/00005072-200606000-00006 16783168
24. J Nakahara S Aiso N Suzuki 2009 Factors that retard remyelination in multiple sclerosis with a focus on TIP30: a novel therapeutic target Expert Opin Ther Targets 13 1375 1376 10.1517/14728220903307491 19839715
25. J Nakahara K Kanekura M Nawa, et al. 2009 Abnormal expression of TIP30 and arrested nucleocytoplasmic transport within oligodendrocyte precursor cells in multiple sclerosis J Clin Invest 119 169 181 19104151
26. Y Pang L Campbell B Zheng, et al. 2010 Lipopolysaccharide-activated microglia induce death of oligodendrocyte progenitor cells and impede their development Neuroscience 166 464 475 10.1016/j.neuroscience.2009.12.040 20035837
27. PY Paterson 1960 Transfer of allergic encephalomyelitis in rats by means of lymph node cells J Exp Med 111 119 136 10.1084/jem.111.1.119 14430853
28. CH Polman PW O'Connor E Havrdova, et al. 2006 A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis N Engl J Med 354 899 910 10.1056/NEJMoa044397 16510744
29. A Reboldi C Coisne D Baumjohann, et al. 2009 C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE Nat Immunol 10 514 523 10.1038/ni.1716 19305396
30. TM Rivers DH Sprunt GP Berry 1933 Observations on attempts to produce acute disseminated encephalomyelitis in monkeys J Exp Med 58 39 53 10.1084/jem.58.1.39 19870180
31. E Roboz-Einstein 1959 Allergic encephalomyelitis as an experimental model for multiple sclerosis Calif Med 91 204 206 13854536
32. M Rodriguez AE Warrington LR Pease 2009 Human natural autoantibodies in the treatment of neurologic disease Neurology 72 1269 1276 10.1212/01.wnl. 0000345662.05861.e4 19349608
33. G Rosati 2001 The prevalence of multiple sclerosis in the world: an update Neurol Sci 22 117 139 10.1007/s100720170011 11603614
34. NH Ruddle CM Bergman KM McGrath, et al. 1990 An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis J Exp Med 172 1193 1200 10.1084/jem.172.4.1193 2212948
35. RA Rudick WH Stuart PA Calabresi, et al. 2006 Natalizumab plus interferon beta-1a for relapsing multiple sclerosis N Eng J Med 354 911 923 10.1056/NEJMoa044396
36. W Schrempf T Ziemssen 2007 Glatiramer acetate: mechanisms of action in multiple sclerosis Autimmun Rev 6 469 475 10.1016/j.autrev.2007.02.003
37. N Scolding R Franklin S Stevens, et al. 1998 Oligodendrocyte progenitors are present in the normal adult human CNS and in the lesions of multiple sclerosis Brain 121 2221 2228 10.1093/brain/121.12.2221 9874475
38. K Selmaj CS Raine M Farooq, et al. 1991 Cytokine cytotoxicity against oligodendrocytes. Apoptosis induced by lymphotoxin J Immunol 147 1522 1529 1908877
39. K Selmaj CS Raine AH Cross 1991 Anti-tumor necrosis factor therapy abrogates autoimmune demyelination Ann Neurol 30 694 700 10.1002/ana.410300510 1722388
40. K Selmaj W Papierz A Glabiński, et al. 1995 Prevention of chronic relapsing experimental autoimmune encephalomyelitis by soluble tumor necrosis factor receptor I J Neuroimmunol 56 135 141 10.1016/0165-5728(94)00139-F 7860709
41. A Setzu JD Lathia C Zhao, et al. 2006 Inflammation stimulates myelination by transplanted oligodendrocyte precursor cells Glia 54 297 303 10.1002/glia.20371 16856149
42. NL Sicotte RR Voskuhl 2001 Onset of multiple sclerosis associated with anti-TNF therapy Neurology 57 1885 1888 11723281
43. S Sriram I Steiner 2005 Experimental allergic encephalomyelitis: a misleading model of multiple sclerosis Ann Neurol 58 939 945 10.1002/ana.20743 16315280
44. L Steinman SS Zamvil 2006 How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis Ann Neurol 60 12 21 10.1002/ana.20913 16802293
45. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group (1999) TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 53:457-465
46. JS Tzartos MA Friese MJ Craner, et al. 2008 Interleukin-17 production in central nervous system-infiltrating T cells and glial cells associated with active disease in multiple sclerosis Am J Pathol 172 146 155 10.2353/ajpath.2008.070690 18156204
47. BW van Oosten M Lai S Hodgkinson, et al. 1997 Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial Neurology 49 351 357 9270561
48. MK Waldor S Sriram R Hardy, et al. 1985 Reversal of experimental allergic encephalomyelitis with monoclonal antibody to a T-cell subset marker Science 227 415 417 10.1126/science.3155574 3155574
49. G Wolswijk 1998 Chronic stage multiple sclerosis lesions contain a relatively quiescent population of oligodendrocyte precursor cells J Neurosci 18 601 609 9425002